Pages that link to "Q74366194"
Jump to navigation
Jump to search
The following pages link to Hepatic dysfunction associated with troglitazone (Q74366194):
Displaying 50 items.
- Advances in diabetes for the millennium: drug therapy of type 2 diabetes (Q24547558) (← links)
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (Q24561401) (← links)
- Update on the treatment of type 2 diabetes mellitus (Q28073342) (← links)
- Fibrates, glitazones, and peroxisome proliferator-activated receptors (Q28279732) (← links)
- Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma (Q28343226) (← links)
- Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase (Q28343312) (← links)
- Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma (Q28366616) (← links)
- Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination (Q28370897) (← links)
- Severe but reversible hepatitis induced by troglitazone (Q28378328) (← links)
- A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability (Q28818450) (← links)
- Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin (Q30307139) (← links)
- A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells (Q33183474) (← links)
- Pharmacological management of diabetes: recent progress and future perspective in daily drug treatment (Q33537440) (← links)
- Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease (Q33607697) (← links)
- Mechanisms by which Thiazolidinediones Enhance Insulin Action (Q33632888) (← links)
- Clinical pharmacokinetics of troglitazone (Q33738078) (← links)
- Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion. (Q33742713) (← links)
- The use of insulin secretagogues in the treatment of type 2 diabetes (Q33752788) (← links)
- FDA approach to the regulation of drugs for diabetes (Q33762025) (← links)
- The glitazones: proceed with caution (Q33973778) (← links)
- A rational approach to drug therapy of type 2 diabetes mellitus (Q33993685) (← links)
- Drug-induced liver disease (Q34057571) (← links)
- Pharmacogenetics of Anti-Diabetes Drugs (Q34181995) (← links)
- Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver (Q34235817) (← links)
- Lessons from the glitazones: a story of drug development (Q34284854) (← links)
- Drug-induced liver disorders: implications for drug development and regulation (Q34303460) (← links)
- Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein (Q34356092) (← links)
- Modern pharmacotherapies for type 2 diabetes mellitus (Q34371607) (← links)
- Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection? (Q34378297) (← links)
- Ongoing challenges in pharmacovigilance (Q34417013) (← links)
- Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges (Q34417044) (← links)
- Oral therapies for diabetic hyperglycemia (Q34451776) (← links)
- Hepatotoxicity with thiazolidinediones: is it a class effect? (Q34458520) (← links)
- A Newly Identified CG301269 Improves Lipid and Glucose Metabolism Without Body Weight Gain Through Activation of Peroxisome Proliferator–Activated Receptor α and γ (Q34527082) (← links)
- Differentiating members of the thiazolidinedione class: a focus on efficacy (Q34580989) (← links)
- Differentiating members of the thiazolidinedione class: a focus on safety (Q34580994) (← links)
- Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records (Q34599640) (← links)
- Hypertension and fatty liver: guilty by association? (Q34608817) (← links)
- Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1. (Q34614106) (← links)
- Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities (Q34625038) (← links)
- PXR, CAR and drug metabolism (Q34743280) (← links)
- Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer (Q34878637) (← links)
- Challenges in optimal metabolic control of diabetes (Q34906359) (← links)
- Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus (Q34977225) (← links)
- Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. (Q34983265) (← links)
- Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors (Q35039274) (← links)
- Hepatotoxicity of the thiazolidinediones (Q35184558) (← links)
- Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? (Q35196709) (← links)
- PPARgamma and metabolism: insights from the study of human genetic variants (Q35200033) (← links)
- Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes (Q35557363) (← links)